Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
160.75
+0.35 (+0.22%)
Official Closing Price
Updated: 7:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about AbbVie
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
54
55
Next >
AbbVie Unusual Options Activity
September 26, 2023
Via
Benzinga
Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher
September 26, 2023
With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio.
Via
InvestorPlace
How Is The Market Feeling About AbbVie?
September 25, 2023
Via
Benzinga
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
September 21, 2023
Many stocks have nosebleed valuations. But not these.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
September 21, 2023
Via
Benzinga
Only 7 Large-Cap Dividend Kings Yield Over 3%. Here's My Top Pick to Buy Now.
September 21, 2023
Dividend Kings are passive income powerhouses, but they aren't always a good value.
Via
The Motley Fool
This Is What Whales Are Betting On AbbVie
September 18, 2023
Via
Benzinga
Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today
September 15, 2023
Via
Benzinga
AbbVie Unusual Options Activity For September 13
September 13, 2023
Via
Benzinga
Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke
September 19, 2023
The company is still figuring out how to gain share in a market topped by AbbVie.
Via
Investor's Business Daily
7 Safe and Steady Dividend Stocks to Buy for Volatile Time
September 19, 2023
Discover how these seven standout companies offer both security and growth potential in an uncertain financial landscape.
Via
InvestorPlace
The Top 7 Underrated Dividend Stocks Yielding 3% or More
September 19, 2023
Investors seeking dependable income and upside should buy these dividend stocks yielding 3% or more, the sooner the better
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
September 18, 2023
Via
Benzinga
2 Dividend Kings to Buy on the Dip and Hold Forever
September 15, 2023
Don't ignore these stocks just because the rest of the market is.
Via
The Motley Fool
2 Undervalued Dividend Stocks to Buy Now
September 13, 2023
These two pharma titans are proven income vehicles.
Via
The Motley Fool
(ABBV) - Analyzing AbbVie's Short Interest
September 08, 2023
Via
Benzinga
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
August 31, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 14, 2023
Via
Benzinga
Why Is Immuno-Oncology Firm Harpoon Therapeutics Stock Trading Lower Today?
September 14, 2023
Harpoon Therapeutics Inc (NASDAQ: HARP) shares are trading lower after AbbVie Inc (NYSE: ABBV) chose not to exercise its exclusive license option within the Development and Option Agreement...
Via
Benzinga
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
September 11, 2023
Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has
Via
Benzinga
3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains
September 05, 2023
These biotech stocks to buy and hold offer tremendous upside blending long-term potential with healthcare advances.
Via
InvestorPlace
The Truth About IPO Investing
September 02, 2023
When most companies go public, they are somewhat mature. Tech company initial public offerings, or IPOs, are a bit different, however. These companies are often not yet profitable. And biotech IPOs are...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Could CVS Make a Copy of Ozempic?
September 02, 2023
Given its new biosimilars unit, copying Ozempic is more likely than it sounds.
Via
The Motley Fool
3 No-Brainer Dividend Stocks to Buy in September
September 02, 2023
Income investors should really like these biopharma stocks with juicy dividends.
Via
The Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
September 02, 2023
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs?
Via
The Motley Fool
CVS Just Made a Major New Announcement, But Should You Buy It?
September 01, 2023
Spinning up a new division will probably be a boon for shareholders.
Via
The Motley Fool
The 3 Most Promising Biotech Stocks to Own Now
August 31, 2023
These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential.
Via
InvestorPlace
Medicare Will Soon Negotiate Some Drug Prices. Is This a Threat to Johnson & Johnson's Earnings?
August 31, 2023
The healthcare giant's immunology drug Stelara brought in more than $9 billion in revenue last year.
Via
The Motley Fool
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
August 29, 2023
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations.
Via
The Motley Fool
Now or Never: 7 Blue-Chip Stocks Offering a Once-in-a-Lifetime Opportunity
August 29, 2023
If you're looking for a once-in-a-lifetime investment opportunity, consider these seven blue-chip stocks to buy now.
Via
InvestorPlace
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.